Zhongshan Laibo Ruichen Biomedicine Co., Ltd.

Home>

The 2nd Meeting of the 2nd Board of Directors & 2025 Annual Shareholders' Meeting of Rabpharma Successfully Concluded

Rabpharma Successfully Recognized as a National High-tech Enterprise

Rabpharma's RAB001 Secures Additional IND Clearance, Expanding into Osteoarthritis

Patient enrollment has been completed for the RAB001 Phase II clinical trial!

Rabpharma Successfully Closes Oversubscribed Series A++ Funding Round to Accelerate R&D Progress